^
Association details:
| Biomarker: | RNF43 mutation |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | nesuparib (JPI-547) (PARP inhibitor, TNKS inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4496 / 21 - JPI-547, a dual inhibitor of PARP/Tankyrase, shows promising antitumor activity against pancreatic cancers with homologous recombination repair deficiency or Wnt-addiction
Published date:
03/15/2023
Excerpt:
Cell lines harboring RNF43 LOF mutations (HPAF-II, AsPC-1, and Capan-2), intrinsically addicted to Wnt/ β-catenin pathway, are more sensitive to JPI-547 than cells with RNF43 wild types.
